Relief Therapeutics Holding SA
RLFTF evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RLFTF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RLFTF
Relief Therapeutics Holding SA (RLFTF) is a Swiss commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with a small portfolio of approved products and a pipeline of product candidates in clinical development.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2023.
Tracking 4 clinical trials for Relief Therapeutics Holding SA.
Relief Therapeutics Holding SA (RLFTF) is a Swiss commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with a small portfolio of approved products and a pipeline of product candidates in clinical development.
- Commercial-stage biopharmaceutical company targeting rare diseases with limited treatment options [sec · filed 2023-05-12].
- As of December 31, 2023, had cash and cash equivalents of CHF 14.6 million and total debt of $17.3M [sec · filed 2024-04-30].
- Net loss of approximately CHF 98.2 million for the year ended December 31, 2023, and accumulated deficit of approximately CHF 218.3 million [sec · filed 2024-04-30].
- Believes current resources are sufficient to fund operations into 2026, but this estimate is based on assumptions that may prove wrong [sec · filed 2024-04-30].
- Depends heavily on the success of its product candidates; failure to obtain regulatory approval or commercialize would materially adversely affect the business [sec · filed 2024-04-30].
What works
- Targets established products with proven safety/efficacy and clear endpoints, allowing for relatively short, capital-efficient clinical trials [sec · filed 2023-05-12].
- Has a small number of approved products generating limited revenue, providing some commercial foundation [sec · filed 2024-04-30].
- Licensed OLPRUVA™ (ACER-001) and added products through acquisitions of AdVita and APR, expanding the pipeline [sec · filed 2024-04-30].
What to weigh
- History of operating losses, negative cash flows, and significant accumulated deficit raise substantial doubt about ability to continue as a going concern [sec · filed 2024-04-30].
- Cash and cash equivalents of CHF 14.6 million as of December 31, 2023, with expectations of increasing expenses for development and commercialization [sec · filed 2024-04-30].
- Dependence on successful clinical development, regulatory approval, and commercialization of product candidates; any delays or failures would materially harm the business [sec · filed 2024-04-30].
- May need additional funding; inability to obtain financing would negatively impact financial condition and ability to pursue business strategies [sec · filed 2024-04-30].
From the filings
Quoted directly from source documents.
The company has a history of operating losses and significant accumulated deficit.
“We incurred a net loss (defined as net loss attributable to owners of the Company) of approximately CHF 98.2 million for the year ended December 31, 2023 and had accumulated losses at consolidation level of approximately CHF 218.3 million as of December 31, 2023.”
SEC filings · April 30, 2024
The company believes it has sufficient resources to fund operations into 2026.
“Based on current financial projections and available cash, we believe that we have sufficient resources to fund operations into 2026.”
SEC filings · April 30, 2024
The company depends heavily on the success of its product candidates.
“We depend heavily on the success of our product candidates. If our clinical studies are unsuccessful, if we or our collaboration partners do not obtain regulatory approval or if we or our collaboration partners are unable to commercialize our product candidates, or if we experience significant delays in doing so, our business, financial condition and results of operations will be materially adversely affected.”
SEC filings · April 30, 2024
The company targets established products with a proven history of safety and efficacy.
“We target established products with a proven history of safety and efficacy and either initial human therapeutic activity, proof-of-concept or a strong scientific rationale, allowing for relatively short, capital-efficient clinical trials with clear endpoints.”
SEC filings · May 12, 2023
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Recurring losses, negative cash flows, and significant accumulated deficit raise substantial doubt about ability to continue as a going concern [sec · filed 2024-04-30].
- Dependence on product candidates — Business heavily depends on successful clinical development, regulatory approval, and commercialization of product candidates; failure would materially adversely affect operations [sec · filed 2024-04-30].
- Need for additional funding — May require additional capital to develop and commercialize product candidates; inability to obtain funding would negatively impact financial condition and business strategies [sec · filed 2024-04-30].
- Limited approved product revenue — Currently has a small number of approved products generating limited sales, making revenue growth dependent on future development success [sec · filed 2024-04-30].
What to watch
- Ability to secure additional financing to extend cash runway beyond 2026 [sec · filed 2024-04-30].
- Progress of clinical studies for product candidates, particularly those with clear endpoints [sec · filed 2023-05-12].
- Regulatory approval outcomes for product candidates in development [sec · filed 2024-04-30].
- Commercialization efforts and revenue generation from approved products and potential new approvals [sec · filed 2024-04-30].
Sources: SEC filings · Generated August 28, 2026 · How we verify sources →
Run Relief Therapeutics Holding SA through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Relief Therapeutics Holding SA facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
2.7 months
D/E 0.46
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for Relief Therapeutics Holding SA?
Relief Therapeutics Holding SA (RLFTF) is a Swiss commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with a small portfolio of approved products and a pipeline of product candidates in clinical development.
Who is the CEO of Relief Therapeutics Holding SA?
Mr. Zachery W. Henderson is the chief executive officer of Relief Therapeutics Holding SA (RLFTF).
Where is Relief Therapeutics Holding SA headquartered?
Relief Therapeutics Holding SA (RLFTF) is headquartered in Geneva, Switzerland.
What therapeutic areas does Relief Therapeutics Holding SA focus on?
Relief Therapeutics Holding SA develops therapies across Oncology, Rare Disease, Neurology, Pain, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.